OSIRIS THERAPEUTICS, INC.

Form 3

November 26, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

SECURITIES

(Print or Type Responses)

1. Name and Address of Reporting

Person *

A Hopper Jonathan Mark

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

11/24/2014

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

OSIRIS THERAPEUTICS, INC. [OSIR]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O OSIRIS THERAPEUTICS, INC., Â 7015 ALBERT EINSTEIN DRIVE

(Street)

Director _X__ Officer

(Check all applicable)

Chief Medical Officer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Person

Form filed by More than One Reporting Person

COLUMBIA. MDÂ 21046

(City) (State) (Zip)

1. Title of Security (Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities

Beneficially Owned

(Instr. 4)

3. Ownership 4. Nature of Indirect Beneficial

Ownership (Instr. 5) Form:

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

4 Conversion or Exercise Price of

6. Nature of Indirect Ownership Beneficial Ownership Form of

(Instr. 5)

Date Exercisable Expiration

Date

Title Amount or Number of

Derivative Security: Security Direct (D)

5.

Derivative

Edgar Filing: OSIRIS THERAPEUTICS, INC. - Form 3

Shares or Indirect (I) (Instr. 5)
Incentive Stock Options (right to buy) $11/24/2014 \stackrel{\text{(1)}}{=} 11/24/2024 \quad \begin{array}{c} \text{Common} \\ \text{Stock} \end{array} \quad 25,000 \quad \$ \; 13.12 \quad \quad D \quad \hat{A}$

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hopper Jonathan Mark C/O OSIRIS THERAPEUTICS, INC. 7015 ALBERT EINSTEIN DRIVE COLUMBIA Â MDÂ 21046	Â	Â	Chief Medical Officer	Â

Signatures

Jonathan M.
Hopper

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Options to purchase 25,000 shares of common stock of the Registrant shall become exercisable with respect to the underlying shares as to (1) 25% on each November 24, 2015, 2016, 2017 and 2018, assuming the Reporting Person continues to be employed by the Registrant on the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2